Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT01911091

Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)

Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation in Both Skeletal Muscle and Adipose Tissue

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
56 (estimated)
Sponsor
AdventHealth Translational Research Institute · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to collect data to help researchers identify factors, such as certain proteins or genetic codes, that are secreted from muscle that are associated with the beneficial effects of exercise.

Detailed description

Study Objectives: 1. To identify specific changes in messenger ribonucleic acid (mRNA)/micro ribonucleic acid (miRNA) expression in muscle associated with higher or lower relative measures of mitochondrial capacity and fat oxidation. 2. To identify secreted factors/miRNAs that specifically relate to the metabolic response of muscle and that are present after a single initial bout of exercise. 3. To collect the appropriate clinical samples (muscle and adipose tissue, plasma/serum) to enable validation of myokines associated with changes in oxygen consumption/mitochondrial content via in vivo and in vitro discovery efforts.

Conditions

Interventions

TypeNameDescription
BEHAVIORALExerciseA 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.

Timeline

Start date
2013-07-01
Primary completion
2014-12-01
Completion
2026-12-01
First posted
2013-07-30
Last updated
2026-03-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01911091. Inclusion in this directory is not an endorsement.